ArticleThorax2019
Incidence of second and higher order smoking-related primary cancers following lung cancer: a population-based cohort study.
Article in Thorax, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04178889 (Second Primary Lung Cancer Cohort Study), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Second Primary Lung Cancer Cohort Study (SPORT)
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Pooled it
- Article
- Semantic CT features and differentiation model: new primary lung cancer versus metastasis after previous malignancy.European radiology · 2026Article
- Utilizing clinical features, genetic mutations, and a 14-gene molecular assay for optimizing the management of multiple primary lung cancer.Translational lung cancer research · 2026Article
- Prediagnostic primary care consultations and imaging in emergency-diagnosed versus referred patients with lung cancer: a population-based linked data study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026Article
- Histology-specific standardized incidence ratio improves the estimation of second primary lung cancer risk.BMC medicine · 2024Article
- Article
- Enhanced Survival with Lymphadenectomy in Early-Stage Metachronous Second Primary Lung Cancer: A Retrospective Analysis.Oncology research and treatment · 2024Article
- Risk factors and prognostic nomogram for patients with second primary cancers after lung cancer using classical statistics and machine learning.Clinical and experimental medicine · 2023Article
- Clinical characteristics of second primary malignancies among first primary malignancy survivors: A single-center study, 2005-2020.Oncology letters · 2023Article
- Multiple primary lung cancer: Updates of clinical management and genomic features.Frontiers in oncology · 2023Review
- Survival Analysis in Patients with Lung Cancer and Subsequent Primary Cancer: A Nationwide Cancer Registry Study.Journal of clinical medicine · 2022Article
- Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment.Radiation oncology (London, England) · 2022Article
- Has the National Fall in Smoking Rates in Ireland Been Replicated in Cancer Patients? A 5-Year Report.International journal of environmental research and public health · 2022Article
- Filling the gaps in the research about second primary malignancies after bladder cancer: Focus on race and histology.Frontiers in public health · 2022Article
- Preliminary study on the molecular features of mutation in multiple primary oral cancer by whole exome sequencing.Frontiers in oncology · 2022Article
- Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study.Scientific reports · 2021Article
- Risk of Second Primary Malignancies in Colon Cancer Patients Treated With Colectomy.Frontiers in oncology · 2020Article
- Article
- Occurrence of Second Primary Malignancies in Patients With Primary Optic Nerve Gliomas: A Surveillance, Epidemiology, and End Results Analysis.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLung cancer 5-year survival has doubled over 15 years. Although the risk of second primary cancer is recognised, quantification over time is lacking. We describe the incidence of second and higher order smoking-related primary cancers in lung cancer survivors, identifying high-incidence groups and how incidence changes over time from first diagnosis.
methodsData on smoking-related primary cancers (lung, laryngeal, head and neck, oesophageal squamous cell carcinoma and bladder) diagnosed in England between 2000 and 2014 were obtained from Public Health England National Cancer Registration and Analysis Service. We calculated absolute incidence rates and standardised incidence rate ratios, both overall and for various subgroups of second primary cancer for up to 10 years from the initial diagnosis of lung cancer, using Poisson regression.
resultsElevated incidence of smoking-related second primary cancer persists for at least 10 years from first lung cancer diagnosis with those aged 50 and 79 at first diagnosis at particularly high risk. The most frequent type of second malignancy was lung cancer although the highest standardised incidence rate ratios were for oesophageal squamous cell carcinoma (2.4) and laryngeal cancers (2.8) and consistently higher in women than in men. Over the last decade, the incidence of second primary lung cancer has doubled.
conclusionLung cancer survivors have increased the incidence of subsequent lung, laryngeal, head and neck and oesophageal squamous cell carcinoma for at least a decade from the first diagnosis. Consideration should be given to increasing routine follow-up from 5 years to 10 years for those at highest risk, alongside surveillance for other smoking-related cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.